Skip to main content
Fig. 2 | Trials

Fig. 2

From: Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial

Fig. 2

a Dosing and titration schedule for each treatment pathway (standard pregabalin dosing, estimated glomerular filtration rate (eGFR) ≥ 60 ml/min). *Participants continue on the maintenance dose of drug from the first treatment phase for the duration of the second treatment phase. b Dosing and titration schedule for each treatment pathway (reduced pregabalin dosing, eGFR 30–59 ml/min). *Participants continue on the maintenance dose of drug from the first treatment phase for the duration of the second treatment phase

Back to article page

Trials

ISSN: 1745-6215